Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Barrington

Adult Reconstructive Orthopaedic Surgery Plano, TX Medical Doctor

NPI 1336120328 CMS profile 60548

6020 W Parker Rd, Ste 470, Plano, TX 75093

Open in the dashboard

General payments

$2,195,433

663 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Barrington of Plano, TX is reported in the CMS Open Payments database as having received $2,195,433 across 663 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $312,540 20
2024 General $147,889 20
2023 General $269,139 48
2022 General $246,010 54
2021 General $188,953 122
2020 General $379,457 89
2019 General $651,444 310

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Barrington
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to John Barrington were reported at $312,540. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year John Barrington Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $651,444 $1,416 $292–$9,336 $163
2020 $379,457 $647 $141–$6,474 $114
2021 $188,953 $1,073 $211–$6,497 $132
2022 $246,010 $1,217 $236–$6,299 $149
2023 $269,139 $1,082 $246–$6,818 $160
2024 $147,889 $1,575 $323–$8,944 $164
2025 $312,540 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $667,232 129 payments
  2. Smith+Nephew, Inc. $608,107 71 payments
  3. Encore Medical, LP $560,670 162 payments
  4. Flexion Therapeutics, Inc. $306,319 261 payments
  5. Kyocera Medical Technologies, Inc. $27,967 7 payments
  6. Pacira Pharmaceuticals Incorporated $17,097 10 payments
  7. Alexion Pharmaceuticals, Inc. $4,080 1 payment
  8. Medical Device Business Services, Inc. $2,750 1 payment
  9. Shalby Advanced Technologies, Inc. $376 2 payments
  10. Maxx Orthopedics, Inc. $253 3 payments
  11. Other $583 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $1,592,373 108 payments
  2. Consulting Fee $272,416 148 payments
  3. Honoraria $256,625 68 payments
  4. Travel and Lodging $65,314 180 payments
  5. Food and Beverage $8,680 156 payments
  6. Education $25 3 payments
Products named General payments · program years 2019–2025
  1. Arcos $524,609 16 payments
  2. Zilretta $306,319 261 payments
  3. JOURNEY II Recon Knees $303,919 29 payments
  4. JOURNEY II Recon Knees $272,774 14 payments
  5. JOURNEY II Recon Knees $234,941 7 payments
  6. DJO SURGICAL Joint Implants $225,713 9 payments
  7. DJO SURGICAL Joint Implants $225,689 8 payments
  8. DJO SURGICAL Joint Implants $225,689 8 payments
  9. Journey II Recon Knees $32,565 8 payments
  10. Oxford $31,982 36 payments
  11. Other $269,879 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,709

Median for Orthopedic Surgery: 203

Drug cost

$9,757

Median for Orthopedic Surgery: $1,433

Branded share of claims

1.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mupirocin Generic 248 $1,758
Dexamethasone Generic 280 $1,494
Ondansetron Hcl Generic 221 $1,432
Tramadol Hcl Generic 248 $1,270
Cephalexin Generic 293 $1,156
Tranexamic Acid Generic 34 $804
Ondansetron Odt Ondansetron Brand 31 $447
Amoxicillin Generic 175 $408
Celecoxib Generic 28 $402
Ibuprofen Generic 46 $248

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$536,143

Of which drugs: $139,959

Medicare patients

893

Average age 75

Services billed

14,251

547 women, 346 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 27%
Depression 19%
Diabetes 18%
Chronic kidney disease 16%
Osteoporosis 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 154 8,712 $119,873
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 23 31 $16,614
Injection, methylprednisolone acetate, 80 mg J1040 Office 44 57 $338
Injection, methylprednisolone acetate, 1 mg J1010 Office 96 931 $89

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $9
$9 — 8,712
Exparel
  • Pacira Pharmaceuticals Incorporated $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

663 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record